Loading...
XSTO
STIL
Market cap198mUSD
Jun 10, Last price  
212.00SEK
1D
0.00%
1Q
-9.79%
Jan 2017
362.88%
Name

Stille AB

Chart & Performance

D1W1MN
P/E
32.73
P/S
3.34
EPS
6.48
Div Yield, %
—
Shrs. gr., 5y
13.29%
Rev. gr., 5y
29.47%
Revenues
570m
+93.27%
96,611,000100,818,00083,411,00089,909,00088,044,00089,095,00081,467,00083,479,00096,334,000121,818,000135,796,000156,673,000142,627,000187,087,000246,350,000294,893,000569,950,000
Net income
58m
+118.44%
-1,773,0005,275,0003,485,000-1,053,000-1,916,0003,288,0001,890,00010,496,00016,789,00014,193,00020,179,00022,879,0008,273,00016,097,00027,324,00026,646,00058,206,000
CFO
74m
+97.27%
3,257,000-797,0001,414,0001,079,0006,984,000-1,725,000-1,351,00010,749,00019,414,00018,946,00013,452,00025,811,00020,556,0007,278,00031,936,00037,277,00073,535,000
Dividend
May 08, 20231.8 SEK/sh
Earnings
Jul 16, 2025

Profile

Stille AB develops, manufactures, and sells surgical instruments in Sweden and internationally. It offers artery forceps and ligature clamps; bone cutters and rongeurs; clamps, curettes, raspatories, elevators, forceps, and micro instruments; needle holders, and wire twisting and holding forceps; and osteotomes, chisels, retractors and skin hooks, scissors, and other products, as well as c-arm tables. The company also provides ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular surgeries. In addition, it provides instrument repair, maintenance, and inspection services. Further, the company's products are used in various open surgeries. It has a collaboration agreement with GE Healthcare and distribution agreement with Synovis Micro. The company sells through OEM manufacturers of C-frames, distributors, and direct sales. The company was founded in 1841 and is headquartered in Torshälla, Sweden. Stille AB is a subsidiary of Linc AB.
URL
https://www.stille.se/
IPO date
Aug 29, 1997
Employees
103
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
569,950
93.27%
294,893
19.70%
246,350
31.68%
Cost of revenue
457,782
252,400
216,722
Unusual Expense (Income)
NOPBT
112,168
42,493
29,628
NOPBT Margin
19.68%
14.41%
12.03%
Operating Taxes
10,964
4,939
5,479
Tax Rate
9.77%
11.62%
18.49%
NOPAT
101,204
37,554
24,149
Net income
58,206
118.44%
26,646
-2.48%
27,324
69.75%
Dividends
(9,024)
(5,013)
Dividend yield
1.19%
0.89%
Proceeds from repurchase of equity
209,219
205,000
BB yield
-11.17%
-27.05%
Debt
Debt current
24,876
12,966
Long-term debt
65,224
83,404
Deferred revenue
Other long-term liabilities
165,460
37,008
32,214
Net debt
(158,485)
(151,346)
59,693
Cash flow
Cash from operating activities
73,535
37,277
31,936
CAPEX
(2,321)
(1,408)
(8,042)
Cash from investing activities
(330,315)
(12,903)
(8,042)
Cash from financing activities
171,400
178,993
(18,539)
FCF
263,150
(187,011)
14,289
Balance
Cash
158,485
241,446
36,677
Long term investments
Excess cash
129,988
226,701
24,360
Stockholders' equity
149,900
121,681
Invested Capital
864,865
582,304
266,830
ROIC
13.99%
8.85%
9.49%
ROCE
12.97%
5.67%
9.56%
EV
Common stock shares outstanding
9,008
5,018
5,013
Price
208.00
37.75%
151.00
34.82%
112.00
-25.58%
Market cap
1,873,754
147.29%
757,730
34.94%
561,510
-25.58%
EV
1,715,269
606,384
621,203
EBITDA
112,168
56,850
39,274
EV/EBITDA
15.29
10.67
15.82
Interest
15,573
10,099
2,336
Interest/NOPBT
13.88%
23.77%
7.88%